Five previously verified CCA serum biomarkers, S100A9, MUC5AC, TGF-β1, angiopoietin-2, and CA19-9 have been validated in the sera from patients by antibody-based methods. This evidence concerns the gene ANGPT2 and cholangiocarcinoma.